Genetic variants A1826H and D2937Y in GAG-β domain of versican inXuence susceptibility to intestinal-type gastric cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 2, 2010, Pages 195-201

  Ju, Hyoungseok ^a   Lim, Byungho ^a   Kim, Minjin ^a   Noh, Seung Moo ^b   Han, Dong Soo ^c   Yu, Hang Jong ^d   Choi, Bo Youl ^e   Kim, Yong Sung ^f   Kim, Woo Ho ^g   Ihm, Chunhwa ^h   Kang, Changwon ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Chungnam National University   (South Korea)

^c Hanyang University Guri Hospital   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Hanyang University   (South Korea)

^f Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^g Seoul National University   (South Korea)

^h Eulji University   (South Korea)

Author keywords

CSPG2; Genetic association; Intestinal type gastric cancer; SNP; Versican

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; VERSICAN; VCAN PROTEIN, HUMAN;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CASE CONTROL STUDY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOMOZYGOTE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HAPLOTYPE; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; STRUCTURAL GENE;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENES, GAG; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; KOREA; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; STOMACH NEOPLASMS; VERSICANS;

EID: 74049134386     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0647-8     Document Type: Article

References (31)

1. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263-265.
2. Boussioutas A, Li H, Liu J, Waring P, Lade S, Holloway AJ, Taupin D, Gorringe K, Haviv I, Desmond PV, Bowtell DD (2003) Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer. Cancer Res 63:2569-2577.
3. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 5:1041-1056.
4. Cattaruzza S, Schiappacassi M, Kimata K, Colombatti A, Perris R (2004) The globular domains of PG-M/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells. FASEB J 18:779-781.
5. Dours-Zimmermann MT, Zimmermann DR (1994) A novel glycosaminoglycan attachment domain identiWed in two alternative splice variants of human versican. J Biol Chem 269:32992-32998.
6. Evanko SP, Angello JC, Wight TN (1999) Formation of hyaluronanand versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:1004-1013.
7. Hippo Y, Taniguchi H, Tsutsumi S, Machida N, Chong JM, Fukayama M, Kodama T, Aburatani H (2002) Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 62:233-240.
8. Kim SY, Kim JH, Lee HS, Noh SM, Song KS, Cho JS, Jeong HY, Kim WH, Yeom YI, Kim NS, Kim S, Yoo HS, Kim YS (2007) Metaand gene set analysis of stomach cancer gene expression data. Mol Cells 24:200-209.
9. Landolt RM, Vaughan L, Winterhalter KH, Zimmermann DR (1995) Versican is selectively expressed in embryonic tissues that act as barriers to neural crest cell migration and axon outgrowth. Development 121:2303-2312.
10. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, Deng Z, Yang BB (2007) The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 67:4742-4750.
11. Lemire JM, Merrilees MJ, Braun KR, Wight TN (2002) Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 190:38-45.
12. Menashe I, Rosenberg PS, Chen BE (2008) PGA: power calculator for case-control genetic association analyses. BMC Genet 9:36.
13. Paulus W, Baur I, Dours-Zimmermann MT, Zimmermann DR (1996) DiVerential expression of versican isoforms in brain tumors. J Neuropathol Exp Neurol 55:528-533.
14. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30:3894-3900.
15. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ (2002) Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 8:1054-1060.
16. Sakko AJ, Ricciardelli C, Mayne K, Tilley WD, Lebaron RG, Horsfall DJ (2001) Versican accumulation in human prostatic Wbroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res 61:926-930.
17. Schmalfeldt M, Dours-Zimmermann MT, Winterhalter KH, Zimmermann DR (1998) Versican V2 is a major extracellular matrix component of the mature bovine brain. J Biol Chem 273:15758-15764.
18. Serrano M, Massague J (2000) Networks of tumor suppressors. Workshop: tumor suppressor networks. EMBO Rep 1:115-119.
19. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, Yang BB (2005) The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 16:1330-1340.
20. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, Wong CK, Lee DY, Yang BB (2006) Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 17:2009-2020.
21. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169.
22. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978-989.
23. Theocharis AD (2008) Versican in health and disease. Connect Tissue Res 49:230-234.
24. Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A (2002) Versican is diVerentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 160:549-557.
25. Wight TN (2002) Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14:617-623.
26. Wight TN, Merrilees MJ (2004) Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ Res 94:1158-1167.
27. Wu Y, Wu J, Lee DY, Yee A, Cao L, Zhang Y, Kiani C, Yang BB (2005) Versican protects cells from oxidative stress-induced apoptosis. Matrix Biol 24:3-13.
28. Yang BL, Zhang Y, Cao L, Yang BB (1999) Cell adhesion and proliferation mediated through the G1 domain of versican. J Cell Biochem 72:210-220.
29. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B (2007) The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 9:R47.
30. Zhang Y, Cao L, Yang BL, Yang BB (1998) The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J Biol Chem 273:21342-21351.
31. Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB (2004) Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 18:754-756.